Gelonghui, March 25, 丨 Giant Biotech (02367.HK) announced that for the year ended December 31, 2023, the company's total revenue was RMB 3,524 billion, an increase of 49.0% over the previous year. The main reason for the increase was that during the reporting period, the company continued to expand product types, deeply cultivate online channels, create star products, and strengthen marketing, which further enhanced the influence of products and brands, and achieved relatively rapid growth in sales revenue. Profit attributable to owners of the parent company was RMB 1,452 million, up 44.9% year on year; basic profit per share was RMB 1.49, up 50.5% from RMB 0.99 for the year ended December 31, 2022.
The company is a leader in the professional skin care products industry based on bioactive ingredients in China. The macro and industry environment in 2023 is full of challenges. The company continues to adhere to the mission of “biotechnology to serve beauty and health”, continue to consolidate R&D advantages, implement industry standards, focus on continuously providing consumers with more high-quality products, enhance brand awareness among a wider range of people, establish a professional and trustworthy brand image, promote omnichannel layout and refined operation, achieve healthy enterprise growth, and help the high-quality development of the recombinant collagen industry.
By the end of the reporting period, the company had been granted and applied for 93 patents, of which 13 were added during the reporting period. The company's recombinant collagen molecular library already has more than 40 types of collagen molecules, and the number remains leading in the industry. By the end of the reporting period, the company had more than 100 research projects. During the reporting period, the company successfully promoted the development and registration of 4 recombinant collagen skin revitalization products.
During the reporting period, the company launched a variety of self-developed raw materials or raw material groups. The rare ginsenoside CK monomer has significant oil control, anti-inflammatory, and acne effects by efficiently regulating the expression of anti-inflammatory related genes. The Kefumei Order series with this as the core ingredient has been well received by consumers since its launch. Specially developed macroglycoside ingredient groups can repair key skin proteins such as collagen and elastin, and exert effects such as redness removal and soothing in products such as collagen milk.
Looking ahead to 2024, the company will continue to increase investment in research and development, promote more breakthroughs in basic technology and the upgrading of raw materials and products, enrich the category matrix, do a good job in clinical and approval of the three types of medical device skin revitalization products, and lay a good foundation for the company's multi-level growth curve. The company will further expand the investment and volume of brand marketing, strive to achieve wider brand exposure while the sales scale is growing, and is committed to promoting the long-term healthy development of the industry.
The company will continue to improve the efficiency of omnichannel operations, especially the refined operation of e-commerce. In the context of increasingly fierce competition, the company will do a good job in crowd operation and scenario design, and create a healthier and more sustainable growth model. In a fully competitive market, the company will not forget its original intention, seize opportunities, adhere to a development path suitable for itself, and bring consumers more beautiful and healthy experiences.